Literature DB >> 19404215

Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China.

Ziming Li1, Yongfeng Yu, Jiade Lu, Qinquan Luo, Chunxiao Wu, Meilin Liao, Ying Zheng, Xinghao Ai, Lingping Gu, Shun Lu.   

Abstract

BACKGROUND: The seventh edition of the tumor, node, metastasis Classification of Malignant Tumors is due to be published in 2009. The recommendations of International Association for the Study of Lung Cancer for changes to the T descriptors have been published. We combined this new parameter with other well-established prognostic factors and performed multivariate survival analyses to validate its value in Chinese stage I non-small cell lung cancer (NSCLC).
METHODS: We try to validate the new staging project in 325 patients who underwent complete surgical resection for stage I NSCLC in Single Institution of Shanghai Chest Hospital from 1998 to 2003. Variables in the analysis included age, gender, performance status, history of smoking, pathologic type, type of resection (pneumonectomy, lobectomy, and bilobectomy), tumor size (greatest dimension of tumor), T-status (T1 or T2), type of lymph node resection (systematic mediastinal lymphadenectomy or mediastinal lymph node sampling), lymphovascular vessel invasion, and adjuvant chemotherapy.
RESULTS: The 5-year overall survival (OS) of patients whose tumor measured no larger than 2 cm in largest diameter or larger than 2 cm but no larger than 3 cm were 75.49 and 74.58%, respectively. For those with tumors measured larger than 3 cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm were 60.87 and 55.63%. The 5-year OS of patients whose tumor measured larger than 7 cm was 46.15% (p = 0.025). The 5-year disease-free survival rates of patients whose tumor measured no larger than 2 cm in largest diameter or larger than 2 cm but no larger than 3 cm were 67.65 and 66.67%, respectively. For those with tumors measured larger than 3 cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm were 53.14 and 52.63%. The 5-year disease-free survival rate of patients whose tumor measured larger than 7 cm was 30.77% (p = 0.009). Multivariate analyses revealed that age, gender, type of resection (pneumonectomy, lobectomy, and bilobectomy), tumor size (greatest dimension of tumor), type of lymph node resection (systematic mediastinal lymphadenectomy or mediastinal lymph node sampling), and lymphovascular vessel invasion were significant predictive factors for OS.
CONCLUSIONS: The tumor size is a significant independent prognostic factors in stage I NSCLC.

Entities:  

Mesh:

Year:  2009        PMID: 19404215     DOI: 10.1097/JTO.0b013e3181a5269d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  19 in total

1.  Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.

Authors:  Jun-Ichi Nitadori; Christos Colovos; Kyuichi Kadota; Camelia S Sima; Inderpal S Sarkaria; Nabil P Rizk; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

2.  Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Authors:  Andrés F Cardona; Oscar Arrieta; Martín Ignacio Zapata; Leonardo Rojas; Beatriz Wills; Noemí Reguart; Niki Karachaliou; Hernán Carranza; Carlos Vargas; Jorge Otero; Pilar Archila; Claudio Martín; Luis Corrales; Mauricio Cuello; Carlos Ortiz; Luis E Pino; Rafael Rosell; Zyanya Lucia Zatarain-Barrón
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

3.  The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma.

Authors:  Wei Wang; Xin Xu; Wujun Wang; Wenlong Shao; Liping Li; Weiqiang Yin; Liangchang Xiu; Mingcong Mo; Jin Zhao; Qingyu He; Jianxing He
Journal:  Tumour Biol       Date:  2011-08-20

4.  Video-assisted thoracoscopic lobectomy for non-small cell lung cancer in patients with severe chronic obstructive pulmonary disease.

Authors:  Wei Wang; Zhiqiang Xu; Xinguo Xiong; Weiqiang Yin; Xin Xu; Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

5.  Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.

Authors:  Jizhuang Luo; Qingyuan Huang; Rui Wang; Baohui Han; Jie Zhang; Heng Zhao; Wentao Fang; Qingquan Luo; Jun Yang; Yunhai Yang; Lei Zhu; Tianxiang Chen; Xinghua Cheng; Yiyang Wang; Jiajie Zheng; Han Wu; Weicong Xia; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-05       Impact factor: 4.553

6.  Descriptive data on cancerous lung lesions detected by auto-fluorescence bronchoscope: A five-year study.

Authors:  Asmitananda Thakur; Lin Gao; Hui Ren; Tian Yang; Tianjun Chen; Mingwei Chen
Journal:  Ann Thorac Med       Date:  2012-01       Impact factor: 2.219

7.  Recommended changes for the 8th edition of the TNM classification for lung cancer-the findings of a single-institution evaluation.

Authors:  Jia Wang; Nan Wu; Chao Lv; Shi Yan; Yue Yang
Journal:  Ann Transl Med       Date:  2020-02

8.  Survival, classifications, and desmosomal plaque genes in non-small cell lung cancer.

Authors:  Laura Boyero; Abel Sánchez-Palencia; Ma Teresa Miranda-León; Fernando Hernández-Escobar; Jose Antonio Gómez-Capilla; Ma Esther Fárez-Vidal
Journal:  Int J Med Sci       Date:  2013-07-10       Impact factor: 3.738

9.  Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.

Authors:  Yan Sun; Xinmin Yu; Xun Shi; Wei Hong; Jun Zhao; Lei Shi
Journal:  World J Surg Oncol       Date:  2014-05-19       Impact factor: 2.754

Review 10.  EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.

Authors:  Shu Fang; Zhehai Wang
Journal:  Drug Des Devel Ther       Date:  2014-09-26       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.